An international overview of the regulatory legislation concerning telemedicine

Telemedicine has been available to healthcare providers for several years. However, it was not until quite recently that the field of telemedicine really took off due to the rise of the COVID-19 pandemic. With the new standard of social distancing and the burden on the healthcare system, the COVID-19 pandemic forced rapid implementation of telemedicine in day-to-day practice, resulting in the use of technology to provide healthcare growing significantly.

This overview is intended to summarise the national developments and legal frameworks with regard to telemedicine in order assist our clients in understanding their position. This document does not constitute legal advice, if you require more information please feel free to reach out to the country contacts in this document.

Read the full document here

Authored by By Katrina Dang, Johanna Harelimana, Christian LindenthalHester BorgersEmma Stok, Enrique Rivas, Pieter ErasmusPatrick Brown

Written by
Katrina Dang
Katrina Dang
I am a junior associate, with experience advising on regulatory and commercial issues, as well as assisting in complex litigation. I have also worked in-house at a FTSE 100 pharmaceutical company. My experience spans across the firm's Intellectual Property, Commercial and Technology & Communications Groups. This exposure to different sectors has allowed me to gain experience in reviewing complex contracts and, in particular, understanding key operational clauses and how they impact upon a client's risk appetite. I have also assisted in drafting terms of use and privacy policies for clients who are entering the Australian market.
Johanna Harelimana
Johanna Harelimana
I am a junior associate, with experience advising clients on regulatory matters across several sectors, especially in life sciences, food and beverages, and environmental sectors. I currently offer both French and international clients legal advice on product's qualification, clinical trials, market access, price and reimbursement, anti-gift regulation, advertising and promotion, e-health (including telemedicine), as well as drafting contracts (distribution, professional services, clinical trial agreements, etc). I also assist with regulatory advice on other products such as cosmetics, biocide, phytopharmaceuticals and novel food.
Christian Lindenthal
Christian Lindenthal
As a partner in our Munich team, I advise clients from the life sciences sector on matters at the interface between IP, unfair competition and regulatory law. I am a member of our Intellectual Property Practice Group as well as our Life Sciences and Healthcare Sector Group. Having an IP background, I specialise in advising clients from heavily regulated industries, most notably from the life sciences sector, but also from related sectors such as food and beverages, and cosmetics. My clients range from global players to innovative start-ups.
Hester Borgers
Hester Borgers
As an associate in our Intellectual Property Group in Amsterdam, I specialise in patent law and life sciences regulatory. I have experience in complex patent litigation, with a strong focus on the medical devices industry and pharmaceutical sector. Furthermore, I assist a broad range of life sciences clients with their regulatory matters, including litigation. My regulatory experience also includes advising with regard to all things digital health - from telemedicine to AI.
Emma Stok
Emma Stok
As an associate in our Intellectual Property Group in The Hague, I offer our clients an all-round IP practice. Within our Intellectual Property Group, I advise and litigate on all areas of Intellectual Property, including patent, trade marks, trade names, product design and copyright matters. I have a special interest in both life sciences and the food industry. As part of our Life Science Regulatory group, I have contributed to international knowledge projects informing our clients of the latest regulatory developments.
Pieter Erasmus
Pieter Erasmus
I am an associate in the Intellectual Property Group in London, with a focus on regulatory and commercial matters primarily in the life sciences and healthcare sectors. Having a keen interest in all things life sciences and healthcare, I specialise primarily in providing regulatory advice in relation to a broad range of regulatory matters in these fields, including pharmaceuticals, medical devices, general healthcare, data protection/privacy (within the healthcare space and otherwise), clinical trials, marketing and advertising of health products, etc. My experience also includes providing regulatory advice in the context of other topics, including films and publications, general commercial and corporate governance, advertising and consumer protection law (regarding health products and other products), cosmetics, foodstuffs, fertilizers, farm feeds, agricultural and stock remedies, and automotive regulation.
Patrick Brown
Patrick Brown
I am an Associate in the Intellectual Property Group in Sydney, with a particular focus on the life sciences, pharmaceutical and chemical sectors. I work in the Intellectual Property Group assisting clients with a wide range of contentious and non-contentious IP matters, including patents, trade marks, plant breeder's rights and breach of confidence. I also work with clients in the life sciences, food, pharmaceutical and consumer healthcare sectors on a range of other matters including regulatory compliance, licensing and distribution agreements.
Enrique Rivas
Enrique Rivas
As a senior associate in the Regulatory & Administrative Group in our Madrid office, I am specialised in both advising and litigating for pharmaceutical, defence and technology companies in matters concerning public law, with a particular focus on public procurement. I advise on public procurement, sanctioning proceedings and liability claims against public bodies. Our clients operate mainly in three sectors, life sciences and healthcare, defence and ICT, which are strategic and particularly innovative industries.

Related articles

Transfers of value to “influencers”: new disclosure obligation for companies in the health sector
The list of beneficiaries of transfers of value subject to compulsory disclosure in the French public...
Managing Scientific Collaboration Agreements within the French Healthtech Sector
Scientific Collaboration Agreements allow a public servant, most of the time a researcher, (who...
The Second Draft Patent Examination Guidelines on Patent Linkage Invalidation, PTE and PTA
TTThe second draft amendment to the Patent Examination Guidelines (the “

Leave a comment